Friday, June 12, 2026

Depo-Provera and Hair Relaxer Dockets Lead Daily Mass-Tort Filings

Women’s health and metabolic drug litigations dominated the federal mass-tort landscape yesterday, driving a concentrated wave of new filings. The surge was led by the Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation (MDL 3140), which logged 34 new complaints as Aylstock Witkin Kreis Overholtz PLLC and Morgan & Morgan PA targeted the contraceptive shot's alleged link to brain tumors. Cosmetic and chemical safety concerns also maintained significant momentum, with the Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (MDL 3060) adding 15 new cases, driven largely by Johnson Law Group and Ashcraft Gerel LLP. Meanwhile, metabolic therapies faced continuing pressure as Morgan & Morgan PA and Seeger Weiss led the filing of 13 new lawsuits in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability (Gastroparesis) Litigation (MDL 3094). Finally, legacy dockets rounded out the day's activity, with the Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation (MDL 2738) logging 5 filings led by Ashcraft Gerel LLP and Goldenberg Lauricella PLLC, and the Paraquat Products Liability Litigation (MDL 3004) recording 4 complaints split between Hochman Law Firm PLLC and Pulaski Kherkher PLLC. See the full filing feed and firm-level breakdowns here.

FDA Releases Establishment Inspection Report for ByHeart Infant Formula

On June 12, 2026, the U.S. Food and Drug Administration's establishment inspection report for the facility manufacturing the base powder for ByHeart infant formula became public, providing critical regulatory details for the ongoing ByHeart, Inc., Infant Formula Marketing, Sales Practices, and Products Liability Litigation (MDL 3178). The 55-page document focuses on the investigation of a late 2025 infant botulism outbreak, concluding that contaminated organic whole milk powder raw material, rather than processing equipment failures, was the likely source of Clostridium botulinum. According to the report, ByHeart officials informed regulators of presumptive-positive test results for the bacteria in early 2026, which matched clinical isolates from affected infants. Plaintiffs' attorneys tracking the consolidated litigation before Judge Arun Subramanian are expected to use these regulatory findings to support claims regarding manufacturing defects and supply-chain oversight as they navigate pretrial discovery. The release of this report marks a key regulatory milestone in the litigation, as parties prepare for upcoming discovery deadlines and pretrial motions.

Assemblies of God Disputes Liability in Chi Alpha Abuse Litigation

On June 12, 2026, the General Council of the Assemblies of God formally disputed liability in the ongoing Assemblies of God Chi Alpha Abuse Litigation, arguing that its organizational structure of local church autonomy shields the national entity from responsibility for sexual abuse committed by a former campus minister. Plaintiffs in the coordinated negligence actions argue that the national council and its regional affiliates failed to investigate the minister's history or warn students of potential dangers. While the denomination has actively fought to block depositions of its high-ranking officials, the litigation experienced a significant shift on June 10, 2026, when a plaintiff filed a motion to dismiss the South Texas District Council following an undisclosed settlement. This partial resolution of claims highlights the escalating stakes for the remaining defendants as they face mounting pressure over institutional accountability. The litigation continues to progress through Texas state courts, where plaintiffs are seeking compensatory damages for systemic oversight failures.